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ABSTRACT
Introduction: Data on triple therapy
(long-acting muscarinic antagonist
[LAMA] ? inhaled corticosteroid/long-acting
beta2-agonist [ICS/LABA]) in symptomatic
patients with chronic obstructive pulmonary
disease (COPD) are limited. This post hoc
analysis aimed to determine the efficacy of
once-daily umeclidinium (UMEC; 62.5 lg) or
placebo (PBO) plus open-label fixed-dose ICS/
LABA in symptomatic patients with COPD.
Methods: Data were pooled from four
randomized, double-blind, parallel-group trials
(ClincalTrials.gov identifiers: NCT01772134,
NCT01772147, NCT01957163, NCT02119286).
Inclusion criteria included COPD diagnosis,
modified Medical Research Council dyspnea scale
scoreC2andforcedexpiratoryvolume in1 s (FEV1)
\70% predicted. Following a 4-week run-in with
once-daily or twice-daily ICS/LABA, patients were
randomized to UMEC 62.5 lg or PBO as add-on
therapy for 12 weeks. The efficacy of
UMEC 62.5 lg? ICS/LABA or PBO? ICS/LABA
in the intent-to-treat (ITT) population and
subgroups with Global initiative for chronic
Obstructive Lung Disease (GOLD) B and D COPD,
and once-daily or twice-daily ICS/LABA was
investigated. Outcomes included: trough FEV1,
rescue-medication use, St George’s Respiratory
Questionnaire (SGRQ) score, moderate/severe
exacerbations. Adverse events (AEs) were assessed.
Results: UMEC 62.5 lg ? ICS/LABA (ITT:
n = 819) provided clinically important
improvements in trough FEV1 versus
PBO ? ICS/LABA [ITT: n = 818; 130 mL (95%
CI 112, 147); P\0.001] at Day 85. Similar
improvements occurred in all four subgroups
(119–147 mL; all P\0.001). In the ITT
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population, UMEC 62.5 lg ? ICS/LABA
decreased rescue-medication use, improved
SGRQ score, and reduced short-term
exacerbation risk (all P B 0.004 versus
PBO ? ICS/LABA). These three outcomes
also improved consistently with
UMEC 62.5 lg ? ICS/LABA versus PBO ? ICS/
LABA with both ICS/LABAs and in the GOLD D
subgroup. In the GOLD B subgroup a
statistically significant benefit was observed in
lung function and proportion of SGRQ
responders. AE incidences were similar with
UMEC 62.5 lg ? ICS/LABA versus PBO ? ICS/
LABA.
Conclusion: In symptomatic patients
with COPD, triple therapy with
UMEC 62.5 lg ? ICS/LABA improved lung
function, reduced rescue-medication use,
improved health-status and reduced
exacerbation risk versus PBO ? ICS/LABA, with
similar safety profiles.
Funding: GSK (study number 202067).
Keywords: Add-on LAMA; COPD; Fluticasone
furoate/vilanterol; Fluticasone propionate/
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is characterized by persistent airflow
obstruction and is a major contributor to
global morbidity and mortality [1].
Bronchodilators [e.g., long-acting beta2
agonists (LABAs) and long-acting muscarinic
antagonists (LAMAs)] are central to the
pharmacological management of symptomatic
COPD [1]. However, use of bronchodilator
monotherapy is frequently associated with
ongoing dyspnea [2]. Combining two
bronchodilators with different mechanisms of
action could increase bronchodilation with
equivalent or fewer side effects compared with
increasing the dose of a single agent [1]. A
common stepwise treatment approach to attain
dual bronchodilation is to co-administer LAMA
and inhaled corticosteroid (ICS)/LABA as triple
therapy [3, 4]. Retrospective large UK database
studies have suggested that this triple regimen is
associated with reductions in exacerbations and
all-cause mortality compared with ICS/LABA
alone [3, 5]. However, the efficacy and safety of
adding a LAMA to ICS/LABA has been tested in
a limited number of randomized, double-blind
clinical trials, and therefore further
investigation is warranted [6, 7].
Umeclidinium bromide 62.5 lg (UMEC,
GSK573719; GSK, London, UK) is a once-daily
LAMA indicated for the maintenance treatment
of patients with symptomatic COPD [8, 9]. Four
studies have examined the efficacy of UMEC
added to once- or twice-daily ICS/LABA therapy,
all of which demonstrated that UMEC (62.5 or
125 lg) ? ICS/LABA improved trough forced
expiratory volume in 1 s (FEV1) compared with
placebo (PBO) ? ICS/LABA [10, 11]. These
individual studies were not powered to detect
treatment differences on patient-reported
outcomes (PROs) and individual studies failed
to demonstrate consistent benefits on PROs [10,
11]. Consequently, an integrated analysis was
designed, pooling the data from all four studies
to examine PROs in greater detail and to also
facilitate subgroup analysis.
Guidelines suggest patients with COPD can
be categorized into one of four Global initiative
for chronic Obstructive Lung Disease (GOLD)
patient groups (A–D) and recommend that
therapy should be prescribed accordingly [1].
As patients in GOLD groups A and C present
with a lower symptom burden than those in
groups B and D [1], groups A and C were
excluded from all four clinical trials examining
triple therapy included in this post hoc analysis
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[10, 11]. Specifically, patients in GOLD group B
and D had moderate-to-severe dyspnea [1].
Additionally, GOLD B included patients with
moderate airflow limitation (FEV1 C50%
predicted) and a low future risk of
exacerbations, whereas GOLD D included
patients with severe-to-very-severe airflow
limitation (FEV1 \50% predicted) and a high
future risk of exacerbations [1].
When prescribing a LAMA added to ICS/
LABA, physicians choose the LAMA and ICS/
LABA combination they consider most likely to
benefit their patients [1]. However, there is little
information in the published literature on
whether the specific type and/or posology of
the ICS/LABA combination, for example, once-
or twice-daily dosing, influences the
incremental effect of LAMA add-on therapy as
a component of open triple therapy.
The aim of this post hoc analysis was
therefore to determine the robustness of the
efficacy and safety of once-daily UMEC
(62.5 lg) ? fixed-dose ICS/LABA compared
with PBO ? fixed-dose ICS/LABA in
symptomatic patients with COPD by pooling
data from four similarly-designed clinical trials.
METHODS
This article is based on previously conducted,
individually reported clinical trials [10, 11], and
did not involve any new clinical trials
performed by any of the authors or any new
primary data relating to patients from any other
source.
This was a post hoc analysis of four 12-week,
Phase III, multicenter, randomized,
double-blind, parallel-group trials comparing
once-daily inhaled UMEC 62.5 lg (delivering
55 lg) ? ICS/LABA with PBO ? ICS/LABA. Two
trials assessed UMEC 62.5 lg ? fluticasone
propionate/salmeterol (FP/SAL; 250/50 lg
twice daily; ClinicalTrials.gov identifiers:
NCT01772134 [AC4116135] and
NCT01772147 [AC4116136] [10]) and two
trials assessed UMEC 62.5 lg ? fluticasone
furoate/vilanterol (FF/VI; 100/25 lg once daily;
delivering 92/22 lg; ClinicalTrials.gov
identifiers: NCT01957163 [200109] and
NCT02119286 [200110] [11]). All four trials
also investigated the add-on benefits of a
higher unlicensed dose of once-daily
UMEC 125 lg ? ICS/LABA, but only the results
from the approved dose of UMEC 62.5 lg ? ICS/
LABA are presented here. It has previously been
shown that both UMEC 62.5 and 125 lg doses
had similar efficacy and safety profiles when
added to ICS/LABA combination therapy in all
of the original studies [10, 11].
Key inclusion criteria of all studies included a
diagnosis of COPD (predicted
post-bronchodilator FEV1 \70% and
FEV1/forced vital capacity \0.70), with a
modified Medical Research Council dyspnea
scale score C2 (i.e., all classified as GOLD B or
GOLD D) [10, 11]. Patients with GOLD D COPD
also had FEV1 \50% predicted or C2
exacerbations (or C1 COPD-related
hospitalization) in the 12 months prior to
enrollment.
All four studies had a similar treatment
design. Enrolled patients entered a 4-week
open-label run-in treatment period with once-
or twice-daily ICS/LABA. At the end of this
period, patients without a COPD exacerbation,
who did not use any of the prohibited
medications and who were 80–120%
compliant with the study drug were
randomized to receive UMEC or PBO added to
the same ICS/LABA treatment for 12 weeks.
Further details of the trial designs have been
previously published [10, 11].
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Post Hoc Analysis
The primary endpoint for the four studies and
the first endpoint examined in this post hoc
analysis was trough FEV1 on Day 85, defined as
the mean of the FEV1 values obtained 23 and
24 h after dosing on Day 84 in the
intent-to-treat (ITT) population. The ITT
population was defined as all patients who
were randomized and received at least one
dose of study drug.
Other assessed efficacy endpoints included:
the proportion of patients achieving an increase
in trough FEV1 above baseline (Day 1) of
C100 mL on Day 85, serial FEV1 post-dose on
Days 1 and 84, weighted mean (WM) FEV1 over
0–6 h post-dose at Day 84, rescue salbutamol/
albuterol use (puffs/day, % rescue-free days),
total St George’s Respiratory Questionnaire
(SGRQ) score, and the proportion of patients
with a SGRQ response (defined as an
improvement of C4 units from baseline) on
Day 84. The incidence of COPD exacerbations
was assessed as a safety endpoint in the original
studies. A moderate/severe COPD exacerbation,
for the purpose of this analysis, was defined as
any acute worsening of COPD symptoms
requiring the use of any antibiotics, systemic
corticosteroids, emergency treatment or
hospitalization.
In this post hoc analysis, these endpoints
were examined in the ITT population and by
subgroup: GOLD B status, GOLD D status,
once-daily FF/VI treatment (studies 200109
and 200110) and twice-daily FP/SAL treatment
(studies AC4116135 and AC4116135).
AEs and serious AEs (SAEs) after the run-in
period were assessed across all studies and are
reported here only for the full pooled ITT
population. AEs of special interest included
those associated with antimuscarinic agents
such as UMEC.
Statistical Analyses
Trough FEV1, 0–6 h WM FEV1, and SGRQ total
score analyses were performed using a repeated
measures model with covariates of study,
treatment, baseline measurement, smoking
status, Day, Day by baseline, and Day by
treatment interactions. Rescue-medication use
(percentage of rescue-free days over the study
duration and mean number of puffs per day)
was analyzed using an analysis of covariance
(ANCOVA) model with covariates of study,
treatment, smoking status and baseline
measurement. The proportion of patients
achieving an increase in trough FEV1 above
baseline of C100 mL on Day 85 and an SGRQ
response were analyzed using logistic regression
with covariates of study, treatment, baseline
measurement and smoking status.
Kaplan–Meier plots were used to plot the time
to first on-treatment COPD exacerbation. Cox
proportional hazard models with covariates of
study, treatment and smoking status at
screening were used to calculate the hazard
ratios (HR) and 95% confidence intervals (CIs)
associated with the time to first exacerbation.
All statistical analyses were performed using SAS
Version 9 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline Characteristics
A total of 3191 patients were recruited to these
four studies, with data from 2458 patients in the
ITT population included in these post hoc
analyses (1637 patients received
UMEC 62.5 lg ? ICS/LABA or PBO ? ICS/
LABA; Fig. 1). Patient demographics and
baseline characteristics were similar across the
two treatment groups (Table 1). In the
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subgroups analyzed, the number of patients
with GOLD B COPD was 320 and 344, and with
GOLD D COPD was 499 and 474 (UMEC
62.5 lg ? ICS/LABA and PBO ? ICS/LABA,
respectively; Table 1). There were 96% and
98% of patients within the GOLD D subgroups
that had severe airflow limitation (FEV1\50%
predicted; UMEC 62.5 lg ? ICS/LABA and
PBO ? ICS/LABA, respectively), while 24% in
each group had experienced one or more COPD




Changes from baseline in trough FEV1 at Day 85
showed clinically important (C100 mL) and
statistically significant improvements for
UMEC 62.5 lg ? ICS/LABA versus PBO ? ICS/
LABA in the ITT population (130 mL; 95% CI
112, 147; P\0.001; Table 2; Fig. 2a). Clinically
important, observed mean improvements in
FEV1 were seen with UMEC 62.5 lg ? ICS/
LABA versus PBO ? ICS/LABA from 3 h after
the first dose of triple therapy (Fig. 2b). Patients
were more likely to achieve a clinically
important increase in trough FEV1 from
baseline at Day 85 with UMEC 62.5 lg ? ICS/
LABA versus PBO ? ICS/LABA (46% vs. 15%;
odds ratio 4.9; 95% CI 3.9, 6.3; P\0.001;
Table 2). For the 0–6 h WM FEV1 at Day 84,
UMEC 62.5 lg ? ICS/LABA provided
statistically significant improvements of
152 mL versus PBO ? ICS/LABA (95% CI 134,







•  200109: 727
•  200110: 730
•  AC4116135: 862
•  AC4116136: 872
•  200109: 619
•  200110: 620
•  AC4116135: 617
•  AC4116136: 608
•  200109: 619
•  200110: 619
•  AC4116135: 614
•  AC4116136: 606
PBO + ICS/LABA 
n=818
•  200109: 206
•  200110: 206
•  AC4116135: 205
•  AC4116136: 201
(Trough FEV1 on Day 85, n=715)
UMEC 62.5 + ICS/LABA 
n=819
•  200109: 206
•  200110: 206
•  AC4116135: 204
•  AC4116136: 203
(Trough FEV1 on Day 85, n=758)
UMEC 125 + ICS/LABA*  
n=821
•  200109: 207
•  200110: 207
•  AC4116135: 205
•  AC4116136: 202
Fig. 1 Summary of patient disposition within the pooled
analysis. (Asterisk) Only the results relating to the approved
dose UMEC 62.5 lg are presented in this paper. The
efﬁcacy and safety outcomes of this investigational dose
have been previously published [10, 11]. FEV1 forced
expiratory volume in 1 s, FF/VI ﬂuticasone furoate/
vilanterol, FP/SAL ﬂuticasone propionate/salmeterol, ICS
inhaled corticosteroid, LABA long-acting beta2 agonist,
PBO placebo, UMEC umeclidinium
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When analyzed by GOLD B/D subgroup,
clinically important and statistically significant
improvements in trough FEV1 from baseline
at Day 85 were achieved with
UMEC 62.5 lg ? ICS/LABA versus PBO ? ICS/
LABA in both subgroups (GOLD B: 147 mL, 95%
CI 118, 175; GOLD D: 119 mL, 95% CI 98, 141;
both P\0.001; Table 3). The 24-h serial FEV1
treatment differences were greater at Days
84–85 versus Days 1–2 in both GOLD
subgroups and appeared to be greater in the
GOLD B population (Fig. 3a, b).
When analyzing lung function by ICS/LABA
combination, UMEC 62.5 lg added to FF/VI
statistically improved trough FEV1 from
baseline at Day 85 versus PBO ? FF/VI
(122 mL, 95% CI 101, 144; P\0.001), with
similar results obtained for UMEC 62.5 lg ?
Table 1 Summary of patient demographics and baseline characteristics (ITT population)




Age, years 63.7 (8.30) 64.1 (8.35)
Sex, n (%)
Male 547 (67) 521 (64)
Current smoker at screeninga, n (%) 376 (46) 402 (49)
Smoking pack-yearsb 47.8 (26.15) 47.6 (25.56)
Baseline pre-bronchodilator FEV1, L 1.26 (0.47) (n = 819) 1.27 (0.48) (n = 815)
GOLD B baseline FEV1 1.59 (0.42) 1.60 (0.44)
GOLD D baseline FEV1 1.05 (0.37) 1.03 (0.35)
Post-salbutamol/albuterol % predicted FEV1 45.3 (12.44) 46.4 (13.04)
Reversible to salbutamol/albuterolc, n (%) 265 (32) (n = 818) 235 (29) (n = 818)
ICS/LABA treatment during run-in, n (%)
FF/VI 412 (50) 412 (50)
FP/SAL 407 (50) 406 (50)
GOLD patient group, n (%)
Total in group B 320 (39) 344 (42)
Total in group D 499 (61) 474 (58)
With FEV1\50% predicted, n 478 464
With FEV1\30% predicted, n 94 108
With C1 exacerbationsd, n 122 115
With C2 exacerbationsd, n 46 32
Puffs of salbutamol/albuterol per daye 2.2 (2.8) 2.0 (2.5)
Percentage of rescue-medication free dayse 43.7 (41.4) 45.3 (42.2)
SGRQ score 44.6 (17.2) 44.6 (17.5)
History of exacerbationsf, n (%)
Required corticosteroid and/or antibiotics 160 (20) 162 (20)
Values are reported as mean (SD) unless otherwise stated. Percentages represent the proportion of the overall ITT population (N = 819 and N = 818)
FEV1 forced expiratory volume in 1 s, FF/VI ﬂuticasone furoate/vilanterol, FP/SAL ﬂuticasone propionate/salmeterol, GOLD Global initiative for chronic
Obstructive Lung Disease, ICS inhaled corticosteroid, ITT intent-to-treat, LABA long-acting beta2 agonist, PBO placebo, SD standard deviation, SGRQ St
George’s Respiratory Questionnaire, UMEC umeclidinium
a Classiﬁed as current smoker if smoked within 6 months
b Smoking pack-years = (number of cigarettes smoked per day/20) 9 number of years smoked
c Reversibility was deﬁned as an increase in FEV1 of C12% and C200 mL following administration of salbutamol/albuterol
d Exacerbations deﬁned as those requiring oral/systemic corticosteroids and/or antibiotics, but not involving hospitalization
e Percentage/mean puffs during week prior to Day 1
f Patients experiencing C1 COPD exacerbation during the 12 months prior to screening
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FP/SAL versus PBO ? FP/SAL (137 mL, 95% CI
110, 164; P\0.001; Table 3). The likelihood of
patients in the UMEC 62.5 lg ? FF/VI treatment
arm achieving an increase of C100 mL in trough
FEV1 at Day 85 versus PBO ? FF/VI was
statistically significant, as was the likelihood
in UMEC 62.5 lg ? FP/SAL versus PBO ? FP/SAL
(both P\0.001; Table 3). The magnitude of
these treatment differences appeared similar
(Table 3). The sustained 24-h efficacy versus
PBO ? ICS/LABA, as assessed via serial FEV1,
appeared similar in patients receiving either
ICS/LABA treatment in combination with
UMEC 62.5 lg (Fig. 3c, d).
Patient-Reported Outcomes
Improvements in rescue-medication use (mean
puffs/day and % rescue-free days; weeks 1–12),
as well as SGRQ total score and SGRQ
responders (at Day 84) were seen with
UMEC 62.5 lg ? ICS/LABA versus PBO ? ICS/
LABA in the ITT population (Table 2). The
SGRQ improvement of -1.55 units was
statistically significant (95% CI -2.51, -0.59;
P = 0.002) and was achieved in addition to ICS/
LABA change from baseline benefits in SGRQ.
Fewer patients experienced a COPD-related
exacerbation with UMEC 62.5 lg ? ICS/LABA
(n = 31, 4%) versus PBO ? ICS/LABA (n = 57,
7%). Treatment with UMEC 62.5 lg ? ICS/LABA
resulted in a 47% risk reduction of a first
exacerbation versus PBO ? ICS/LABA (HR 0.53;
95% CI 0.34, 0.82; P = 0.004; Fig. 4a).
UMEC 62.5 lg ? ICS/LABA statistically
improved rescue-medication use, change from
baseline in SGRQ total score and the proportion
of SGRQ responders versus PBO ? ICS/LABA in
the GOLD D subgroup (Table 3). Although there
was a trend for improvements in PROs in the
GOLD B subgroup, only the proportion of SGRQ
responders with UMEC 62.5 lg ? ICS/LABA was
statistically significant versus PBO ? ICS/LABA
(Table 3). Only patients in GOLD D showed a
statistically significant reduction in the risk of a
first exacerbation with UMEC 62.5 lg ? ICS/
LABA (23 patients with an exacerbation; 5%)
versus PBO ? ICS/LABA (39 patients with an
exacerbation; 8%; reduction of 49%; HR 0.51;
95% CI 0.30, 0.86; P = 0.012; Fig. 4b). The
magnitude of effect seen in the GOLD B
subgroup was similar to that in the GOLD D
subgroup, with an apparent risk reduction of
56% for a first exacerbation with UMEC
62.5 lg ? ICS/LABA (8 patients with an
exacerbation; 3%) versus PBO ? ICS/LABA (18
patients with an exacerbation; 5%), but this
difference failed to reach statistical significance
(HR 0.44; 95% CI 0.19, 1.02; P = 0.055; Fig. 4b).
UMEC 62.5 lg added to either FF/VI or FP/
SAL resulted in similar improvements in
rescue-medication use and SGRQ scores
(Table 3). Each of these improvements were
statistically significant versus PBO ? ICS/LABA
(all P\0.05; Table 3). A total of 12 patients (3%)
treated with UMEC 62.5 lg ? FF/VI experienced
a moderate/severe exacerbation versus 24
patients (6%) treated with PBO ? FF/VI (HR
0.47; 95% CI 0.23, 0.94; P = 0.033). There
appeared to be a reduction in the risk of
COPD exacerbations for patients treated with
UMEC 62.5 lg ? FP/SAL (19 patients with an
exacerbation; 5%) compared with PBO ? FP/
SAL (33 patients with an exacerbation; 8%);
however, this was not statistically significant
(HR 0.58; 95% CI 0.33, 1.02; P = 0.058; Fig. 4b).
Safety
The overall incidence of AEs was similar across
treatment groups, with nasopharyngitis,
headache and back pain the most commonly
reported AEs (Table 4). The incidences of AEs of
special interest (which included pneumonia,
lower respiratory tract infection and
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cardiovascular events) were similar or lower in
the UMEC 62.5 lg ? ICS/LABA versus
PBO ? ICS/LABA groups.
A total of eight fatal SAEs were reported in
these two treatment arms, none of which was
considered related to the study treatment. Two
deaths occurred in the UMEC 62.5 lg ? ICS/
LABA group (one due to gastric ulcer
hemorrhage with myocardial infarction and
one to lymphoma). There were six deaths in
Table 2 Lung function, rescue use and SGRQ endpoint comparisons (ITT population)




Trough FEV1 (Day 85)
n 758 715
D from baseline, mL 112 (6.2) -18 (6.3)
vs. PBO ? ICS/LABA (95% CI)a 130 (112, 147)* –
% Patients achieving D from
baseline of C100 mL in FEV1 (Day 85)
n 819 814
Responders, n (%) 377 (46) 121 (15)
vs. PBO ? ICS/LABA, odds ratio (95% CI)b 4.9 (3.9, 6.3)* –
0–6 h WM FEV1 (Day 84)
n 754 718
D from baseline, mL 186 (6.4) 34 (6.5)
vs. PBO ? ICS/LABA (95% CI)a 152 (134, 170)* –
Rescue-medication use, mean puffs/day
n 776 743
D from baseline -0.5 (0.04) -0.2 (0.04)
vs. PBO ? ICS/LABA (95% CI)c -0.3 (-0.4, -0.2)* –
% Rescue-free days
n 776 743
D from baseline 10.4 (0.88) 3.3 (0.90)
vs. PBO ? ICS/LABA (95% CI)c 7.1 (4.6, 9.5)* –
SGRQ total score (Day 84)
n 748 719
D from baseline -2.91 (0.34) -1.36 (0.35)
vs. PBO ? ICS/LABA (95% CI)a -1.55 (-2.51, -0.59) –
SGRQ responders (Day 84)
n 791 784
Responders, n (%) 324 (41) 240 (31)
vs. PBO ? ICS/LABA, odds ratio (95% CI)b 1.6 (1.3, 2.0)* –
Values are reported as LS mean (SE) unless otherwise stated
ANCOVA analysis of covariance, CI conﬁdence interval, D Change, FEV1 forced expiratory volume in 1 s, PBO placebo, ICS inhaled corticosteroids, ITT
intent-to-treat, LABA long-acting beta2 agonist, LS least squares, PBO placebo, SE standard error, SGRQ St George’s Respiratory Questionnaire, UMEC
umeclidinium, WM weighted mean
* P\0.001 vs. PBO ? ICS/LABA
 P = 0.002 vs. PBO ? ICS/LABA
a Analysis performed using a repeated measures model
b Analysis performed using logistic regression
c Analysis performed using an ANCOVA model
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the PBO ? ICS/LABA group (three due to
myocardial infarctions, one to
cardio-respiratory arrest, one to cardiac arrest
and one to pneumonia). Further details on these
events have been previously published [10, 11].
DISCUSSION
In this pooled analysis of four replicated 12-week
lung-function studies performed in patientswith
symptomatic COPD, UMEC 62.5 lg added to a
background of open-label ICS/LABA treatment
resulted in clinically important improvements in
trough FEV1 (C100 mL) versus PBO ? ICS/LABA
in the ITT population and all subgroups.
Improvements in serial FEV1 were evident
15 min after the first dose of
UMEC 62.5 lg ? ICS/LABA, and by 3 h a mean
increase of C100 mL from PBO ? ICS/LABA was
achieved. This level of improvement was
maintained to the last study dose in all four
study subgroups. In the overall ITT population,
UMEC 62.5 lg ? ICS/LABA improved all PROs
including daily rescue medication use (a marker
of a patient’s daily symptomatology) and
health-related quality of life, as well as reducing
the risk of a first moderate/severe COPD
exacerbation versus PBO ? ICS/LABA. This
study therefore demonstrates that a stepwise
increase to triple therapy may be beneficial for
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Fig. 2 Change from
baseline in trough
FEV1 at Day 85 (a;
ITT population), ﬁrst





in 24-h serial FEV1
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A surprising finding of this pooled post hoc
analysis was that the magnitude of
improvements in lung function were
remarkably consistent in all subgroups, as well
as with those reported in previous trials
investigating UMEC 62.5 lg as a monotherapy
[12–14]. This suggests that symptomatic
patients treated with combination ICS/LABA
often have the potential for clinically important
improvements in lung function [15]. The
consistency of improvement observed with all
other endpoints when examining
UMEC 62.5 lg ? ICS/LABA versus PBO ? ICS/
LABA in the overall ITT population is also
supportive of this view. Moreover, in contrast
with the individual studies, which were
powered to only examine lung function
outcomes, the analysis of pooled data resulted
in far more consistent changes in PROs [10, 11].
When analyzing patients by GOLD B and
GOLB D subgroups, improvements in lung
function with UMEC 62.5 lg ? ICS/LABA
versus PBO ? ICS/LABA were numerically
greater in patients with better lung function at
study entry, i.e., patients with GOLD B versus
GOLD D COPD. These improvements in
symptomatic patients with GOLD B COPD
using ICS/LABA therapy could challenge
recommendations that triple therapy should
be reserved for patients only with GOLD D
COPD.
In contrast to the lung function findings,
patients in the GOLD D subgroup showed a
greater symptomatic benefit with triple therapy
versus PBO ? ICS/LABA than patients in GOLD
B based on reductions in daily
rescue-medication use and changes in SGRQ
total score. Despite this finding, it was
notable that a similar increase in the
proportion of patients deriving a clinically
important increase in health status (SGRQ
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with triple therapy versus PBO ? ICS/LABA in
both GOLD B and GOLD D patient subgroups.
In support of this finding, similar reductions in
COPD exacerbation risk (UMEC 62.5 lg ? ICS/
LABA versus PBO ? ICS/LABA) were also
observed in both GOLD B and D subgroups,
although the reduction in the GOLD B
subgroup was not statistically significant.
In this post hoc pooled analysis, we also
examined the influence of the type of ICS/LABA
therapy used concomitantly in the four studies,
as well as whether once-daily or twice-daily ICS/
LABA therapy provided a different opportunity
to demonstrate an incremental efficacy gain
when stepping up therapy with the addition of
UMEC 62.5 lg. Reassuringly, we found that this
aspect of the study design had little impact on
the study findings, as efficacy improvements
were consistently seen with UMEC 62.5 lg as
part of an open triple regimen, irrespective of
the dosing regimen of the concurrent ICS/LABA
therapy.
Currently, there is a paucity of data showing
the benefit of open triple therapy compared
with ICS/LABA on COPD exacerbations. For
both moderate (requiring a prescription of oral
corticosteroids) and severe (resulting in
hospitalizations) exacerbations, the benefit of
adding a LAMA to ICS/LABA therapy is
currently only well-documented in the context
of a large real-world database study [5]. Data
from large long-term randomized controlled
trials (RCTs) to corroborate this finding are
lacking. Among the limited number of RCTs
reported, Aaron et al. [17] failed to show a clear
benefit of triple therapy (tiotropium ? FP/SAL)
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Fig. 3 First and last dose treatment differences
(UMEC 62.5 lg ICS/LABA versus PBO ? ICS/LABA)
in 24-h serial FEV1 by the GOLD patient subgroup B (a),
subgroup D (b), and by ICS/LABA combination FF/VI
(c) and FP/SAL (d). CI conﬁdence interval, FEV1 forced
expiratory volume in 1 s, GOLD Global initiative for
chronic Obstructive Lung Disease, ICS inhaled corticos-
teroid, LABA long-acting beta2 agonist, LS least squares,
MCID minimal clinically important difference (deﬁned as
a C100 mL treatment difference), PBO placebo, UMEC
umeclidinium
54 Pulm Ther (2016) 2:43–58
versus tiotropium on moderate exacerbations in
a small, 12-month study confounded by very
high dropout rates. However, they were able to
show a reduction in severe exacerbations with
triple therapy [17]. In this post hoc analysis of
over 1600 patients, despite the short study
length, we found a statistically significant
reduction in the risk of a first moderate/severe
exacerbation when adding UMEC 62.5 lg to
ICS/LABA therapy. This finding was consistent
across subgroups, despite the low number of
events reported. One other larger, but shorter
(3 months) study of triple therapy versus
tiotropium corroborates these findings [18]. As
high dropout rates may confound many
long-term exacerbation studies performed in
high-risk patients [17, 19], the approach of
pooling data from short-term studies may
provide an alternative insight on how best to
examine exacerbations in higher-risk patients
with COPD. However, it is important to
recognize a key limitation of our findings: that
they have been obtained as part of a post hoc
analysis. Caution is also needed in generalizing
the magnitude of the exacerbation benefits
observed here, as experience of a previous
exacerbation was not an inclusion criteria for
the study, thereby potentially minimizing the
level of events observed.
UMEC 62.5 lg open triple therapy was well
tolerated and did not increase the overall
incidence of AEs or cardiovascular AEs or SAEs
versus PBO ? ICS/LABA. The overall incidence
of SAEs (fatal and non-fatal) in this short study
period was low in both treatment groups and
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therapy. Further research is therefore warranted
to verify these findings in a large, prospective
RCT. The InforMing the PAthway of COPD
Treatment (IMPACT; ClinicalTrials.gov
identifier: NCT02164513) study is currently
ongoing and may answer some of these critical
questions regarding COPD treatment [20].
Active pharmacovigilance evaluation of these
treatments is also underway to further
characterize their safety profiles.
The strengths of this post hoc analysis were
that it included four studies with high
completion and retention rates. The design of
these double-blind, PBO-controlled studies was
robust. Two replicate studies were performed for
addition of UMEC to FP/SAL and to FF/VI, thus
confirming efficacy and safety results. Although
these post hoc analyses used data pooled from
four studies of short duration, they provide new
information about UMEC 62.5 lg added to ICS/
LABA. Additional studies could compare triple
therapy to LAMA/LABA dual therapy, to
ascertain the treatment benefits of ICS in the
triple combination. Our analysis also focused
only on the GOLD guidelines in place at the
time of the study, dividing patients into
subgroups based on the A–D classification, but
lacked data in less symptomatic patients in
groups A and C. As the GOLD guidelines are
updated annually, future analyses may require
further refinement. The current GOLD
guidelines have limited information on
phenotypes such as the asthma–COPD overlap
syndrome [1]. In an attempt to address such
limitations, other national guidelines for the
treatment of patients with COPD have been
developed, for example, in Spain [21], Finland
[22] and the Czech Republic [23]. Future studies
could investigate which specific phenotypes,
highlighted in these national guidelines
[21–23], would benefit from triple therapy
with LAMA ? ICS/LABA.
Table 4 Overview of AEs (ITT population)




Any on-treatment AE 298 (36) 312 (38)
Non-fatal SAEs (any event) 18 (2) 34 (4)
Fatal SAEs (any event) 2 (\1) 6 (\1)
AE reported by C3% patients
Nasopharyngitis 29 (4) 48 (6)
Headache 35 (4) 30 (4)
Back pain 22 (3) 17 (2)
AEs of special interest
Pneumonia, any event 6 (\1) 11 (1)
LRTI excluding pneumonia, any event 3 (\1) 5 (\1)
Cardiovascular events, any event 19 (2) 29 (4)
All data are presented as n (%)
AE adverse event, ICS inhaled corticosteroid, ITT intent-to-treat, LABA long-acting beta2 agonist, LRTI lower respiratory
tract infection, PBO placebo, SAE serious adverse event, UMEC umeclidinium
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CONCLUSIONS
UMEC 62.5 lg added to ICS/LABA provided
clinically important improvements in lung
function from the first to the last dose of
treatment, versus PBO ? ICS/LABA in
symptomatic patients with COPD. These lung
function improvements occurred irrespective of
GOLD B or D classification or the ICS/LABA
regimen used. UMEC 62.5 lg triple therapy was
well tolerated and improved daily rescue
medication use and health-related quality of
life, and reduced the risk of moderate/severe
COPD exacerbations in the short 3-month
follow-up period.
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